0001209191-17-002291.txt : 20170105 0001209191-17-002291.hdr.sgml : 20170105 20170105175738 ACCESSION NUMBER: 0001209191-17-002291 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170103 FILED AS OF DATE: 20170105 DATE AS OF CHANGE: 20170105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 BROOKLINE STREET STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 130 BROOKLINE STREET STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bell Graeme CENTRAL INDEX KEY: 0001643757 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 17512155 MAIL ADDRESS: STREET 1: 1324 WAVERLY ROAD CITY: GLADWYNE STATE: PA ZIP: 19035 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-03 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001643757 Bell Graeme C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Financial Officer Stock Option (right to buy) 13.48 2017-01-03 4 A 0 210000 0.00 A 2027-01-02 Common Stock 210000 210000 D This option was granted on January 3, 2017 with respect to 210,000 shares of Common Stock, with 25% vesting on December 12, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. /s/ Nicole Heifner, attorney-in-fact 2017-01-05